Background. Predictive performance of eleven published propofol pharmacokinetic models was evaluated for long-duration propofol infusion in children. Methods. Twenty-one aged three-11 yr ASA I-II patients were included. Anaesthesia was induced with propofol or sevoflurane, and maintained with propofol, remifentanil, and fentanyl. Propofol was continuously infused at rates of 4-14 mg kg
The accuracy of TCI depends highly on the accuracy of the applied PK model to predict the time course of the plasma concentration and to control infusion rates. Of particular importance for long-duration anaesthesia is the possibility for systematic changes in PK model predictive performance over time. Predictive performance of a PK model early in a patient could differ from those later in the same patient and give the clinician a false impression of stability (or instability) of anaesthetic conditions. Deterioration of predictive performance of a PK model over time might result in unrecognised under-or over-dosing of propofol. This might lead to adverse effects such as intraoperative awareness, delayed emergence from anaesthesia, or misinterpreted haemodynamic instability. Previously, predictive performances of paediatric PK models have only been evaluated for limited durations of propofol infusion up to three h. One study 5 has assessed eight models [6] [7] [8] [9] [10] [11] [12] [13] during propofol infusion over 99 (31) min (mean (SD)) and over two h after surgery in three-26 month children using arterial samples. Another study 11 evaluated eight models 6-10 14-16 up to 45 min after start of propofol infusion using TCI in children four-11 yr of age using venous samples. Although the Paedfusor 6 and Marsh (for adults) models were simultaneously assessed in children nine-17 yr old for up to six h, 17 the performance of published paediatric PK models for long-duration anaesthesia has not been evaluated. The aim of the study was to examine the prediction accuracy of published propofol PK models for anaesthesia of > two h duration in children. The hypothesis was that PK models can predict propofol Cp for long-duration anaesthesia with acceptable prediction stability judged on the following three criteria: divergence prediction error (PE) between -4% h À1 and 4% h À1 with median prediction error (MDPE) between -20% and 20% and median absolute prediction error (MDAPE) < 30%.
Methods
This prospective observational study was approved by the institutional research and ethics committee of Chiba Children's Hospital (Chiba, Japan). After obtaining written informed consent from the parents of each paediatric patient, we enrolled patients of three to 11 yr of age, ASA physical status I or II, and undergoing tympanoplasty, cranioplasty, cleft lip correction, or orthopaedic surgery. We included patients with expected anaesthesia times of > two h. Exclusion criteria included morbid obesity, congenital heart disease, liver or renal dysfunction, neurological disorder, and allergy to soybeans or eggs.
Clinical protocol
Patients were not premedicated and were monitored using ECG, non-invasive bp, pulse oximetry, and capnography. Anaesthesia was induced with propofol, remifentanil, and fentanyl via a peripheral i.v. line, or with sevoflurane and nitrous oxide in oxygen via face mask. After rocuronium was administered, the trachea was intubated. Anaesthesia was maintained with propofol, remifentanil, and fentanyl. Propofol was continuously infused at rates between four and 14 mg kg À1 h À1 after an initial bolus of 1.5 or 2.0 mg kg
À1
. Remifentanil infusion was started at a rate of 0.5 lg ml À1 min À1 and fentanyl 1-2 lg kg À1 was given as an initial bolus. Infusion rates of propofol and remifentanil were adjusted and additional doses of fentanyl was given as required.
Sample acquisition and drug assay
For blood sampling, we used a 22 gauge peripheral venous catheter at a limb on the opposite side of the i.v. line for propofol administration. Venous blood samples (0.5 ml each) were obtained every 30-60 min for up to five h and every 60-120 min after five h from the start of propofol administration during the maintenance of anaesthesia, and immediately after the end of propofol administration. After a change of dose rate of propofol, we avoided drawing blood samples for five min. Blood samples were centrifuged and plasma was kept at À30 C until assayed.
Venous plasma concentrations (Cp) of propofol were determined using high-performance liquid chromatography.
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PK models studied
We selected eleven published PK models of propofol; nine models for children (Paedfusor, 6 Kataria, 7 Marsh, 8 Short, 9 RigbyJones, 10 Coppens
11
, Saint-Maurice 12 , Shangguan 14 , and Murat 13 models); and two general-purpose models for children and adults (Schü ttler 15 and Eleveld 19 models). All were developed as three compartment models. The pharmacokinetic parameter sets applied in the present study and the background of the PK model development including patient age, dose regimen of propofol, and blood sampling are shown in Tables 1 and 2 . The detailed background of the Paedfusor model including subject characteristics, dose regimen of propofol, and blood sampling have not been described. 6 15 20 The range of age in subjects was limited, (i.e. four to seven, four to seven or one to three yr), for development of the Short, Saint-Maurice, and Murat models, respectively. Only bolus dosing was performed for the SaintMaurice, Shangguan, and Murat models. Arterial blood samples were obtained for the Rigby-Jones and Shangguan models, both arterial and venous samples for the Schü ttler and Eleveld models, and venous samples for the remaining seven models. For the Marsh and Short models, external evaluation was performed to confirm robustness of the models using data which were excluded from the model development. Details of model development can be found in the original articles.
Model evaluation
A goodness-of-fit plot was produced for each pharmacokinetic model. The plot depicted prediction error (PE) as the y-axis against time as the x-axis, in individuals to clarify the timerelated bias of the prediction. For each measurement of propofol Cp, PE (%) was determined as (measured Cp -predicted Cp)/predicted Cp Â 100, where predicted Cp was calculated using the assessed PK model. When an applied model perfectly predicts Cp (i.e. the predicted Cp is equal to the measured Cp), then the corresponding PE value is 0%.
Editor's key points
• Pharmacokinetic models are useful in predicting plasma concentrations for target-controlled infusion (TCI), but the various models differ in their predictive performance.
• The performance of 11 pharmacokinetic models was evaluated for propofol TCI in 21 children undergoing long-term infusions.
• Two of the models had acceptable performance in predicting measured plasma propofol concentrations, and are preferred for use in long duration propofol TCI.
The predictive performances of the eleven PK models were evaluated using the PE derivatives proposed by Varvel and colleagues. 21 For each individual, MDPE and MDAPE were calculated. MDPE reflects the bias of the Cp prediction. An MDPE value of 0 means no bias. MDAPE indicates the inaccuracy of the Cp prediction. The closer MDAPE is to 0, the more accurate is the model. We determined divergence APE, which is the original divergence defined by Varvel and collegues, 21 and divergence PE, which has been proposed by Glen and collegues. 22 The divergence APE and divergence PE were calculated as the slope of linear regression of APE and PE against time, respectively. An absolute value of the divergence close to 0 means that prediction is stable over time. 
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0.75 (2) . Larger values of this metric indicate better prediction of the model. The metric becomes 100% when all observations have APE 20%, while the metric is -100% when all observations have APE > 60%. We calculated predicted performance metrics for all sampling times, for earlier sampling time 180 min (180 min was the mean of sampling times), and for later sampling time > 180 min after the start of propofol administration.
Statistics
Sample size was determined as 20 to detect 4% h À1 difference of divergence PE from 0 with SD of 6% h À1 based on a power of 0.8
and an alpha of 0.05. We assumed that this difference is a reasonable criterion without substantive prior data. Data are presented as mean (SD) (range). One sample Student's t-test was used to examine whether a mean value of divergence PE was different from zero. To illustrate the typical model behaviour for PE against time, we applied Friedman's supersmoother curve in the figures. The Tukey test was used for multiple comparison of divergence APE and Wobble between the groups. Multiplicity adjusted P value was applied as P value. Linear regression analysis was used to examine the relationship between total body weight and age. P value <0.05 was regarded as significant. Statistical analyses were performed using Prism 7.00 (GraphPad Software, La Jolla, CA, USA) and R version 3.2.2 (http://www.R-project.org/).
Results
We included all recruited paediatric patients (15 male, six female). Their characteristics were 7 (3) (three-11) yr, 24 (7) (15-40) kg total body weight, 120 (16) . Predicted Cp for eleven pharmacokinetic models are shown in Fig. 2 . The Shangguan model predicted higher propofol Cp than the other models, especially at later sampling points.
The goodness-of-fit plots for PE are shown in Fig. 3 . The white band between -20% and 20% of PE indicates good performance, while the dark grey bands below -60% and above 60% indicate poor performance of the model. The red curve is Friedman's supersmoother, a highly automated variable span smoother, 24 which describes the typical model behaviour in the population. The entire red curves for the Short models fall within the white band indicating good performance, and half of the red curve for the Shangguan model lies in the dark grey band indicating poor performance. PE derivatives including MDPE, MDAPE, divergence APE, divergence PE, and Wobble are shown in Table 3 . The best three models (predictive performance metric) were the Short (63.5%), Kataria (61.2%), and Murat (58.8%) models for all sampling times. The predictive performance metric for all sampling times in the Schü ttler and Eleveld models were 47.1% and 40.0%, respectively. The three best models for the earlier sampling times of 180 min were the Short (75.5%), Kataria (75.5%), and Saint-Maurice (67.3%) models, and the three best models for the later sampling times >180 min were the Murat (50.0%), Short (47.2%), Kataria (41.7%) models.
Discussion
The Short and Schü ttler models predicted propofol Cp with acceptable performance over long-duration paediatric anaesthesia up to 545 min, with divergence PE values of -1.9% h À1 and -2.8% h
À1
, respectively. The Marsh, Rigby-Jones, Coppens, and Eleveld models had acceptable divergence PE values with unacceptable negative bias of prediction. The remaining five models resulted in unacceptable negative divergence PE.
Overall the Short model best described the time course of propofol concentration, as also found by a previous evaluation study 5 although the patient age of the evaluation datasets (three to 11 yr vs three to 26 months, respectively) and the sampling sites (venous vs arterial) between the studies were different. The pharmacokinetic properties of propofol between different age groups can be expected to be unequal. The activities of the main enzymes metabolizing propofol 25 , uridine diphosphate glucuronosyl transferase and cytochrome P450, are lower in infants than in preschool/school-aged children. 26 This variation of enzymatic activities suggests that propofol can be metabolized faster in older subjects of the present study (three to 11 yr) than in younger subjects of the previous study (three to 26 months). The sampling site might also influence the performance of a PK model prediction. Arterial Cp of propofol was higher than venous Cp during and for a short period after a slow bolus infusion in adults. 27 The impact of sampling site is small in the present study as we took blood samples at steady-state. Although the reason why these two studies selected the same model as the best is unclear, other differences in pharmacokinetic properties such as larger distribution volume in infants than in older children resulting in lower propofol Cp might also influence the results in these two studies. Another PK model evaluation 11 reported that the Marsh model performed better than the Short, Rigby-Jones, and Schü ttler models. One difference between the previous and present studies was that the sampling duration in the present study was longer than that in the previous study, although patient ages were similar. The sampling duration of datasets for evaluation and for model development could influence model selection in the present study, possibly associated with the longer terminal half-life of propofol (209 min) in children. 28 In the development of the Short model, sampling duration was longer (four h) than that of the Marsh model (two h). Longer sampling might be a reason that the Short model predicted Cp better than the Marsh model in the present study. The number of samples during non-steady-state infusion might also influence the predictive performance which can be influenced by infusion phases such as rapid infusion, maintenance, and recovery phases. 22 In the present study, all samples were obtained during the maintenance of anaesthesia, while approximately half of samples were obtained at non-steady state in the early phase after rapid infusion and recovery phases in the previous study.
11
The Short model was developed using a single dataset including the following conditions: (1) propofol was infused continuously up to 108 min, (2) all subjects were paediatric patients whose ages (four-seven yr) were similar to those in this study (three-11 yr), and (3) samples were obtained after the end of propofol infusion over ! two h ( Table 2) . As the infusion-duration for development of the Short model (18-108 min) was shorter than our dataset (88-545 min), the similar method of delivery (continuous infusion), similar population, and also longduration sampling including the elimination phase seem to be advantageous for predictive ability of PK models. Although population for the development of the Kataria (three-11 yr, 15-61 kg, 83-146 cm) and Coppens models (four-11 yr, 18-54 kg, 105-152 cm) were also similar to our patients (three-11 yr, 15-40 kg, 95-146 cm), the predictive performance was not acceptable. In the development of the Coppens model, sampling time after the end of continuous infusion was 15 min, which was much shorter than that of the Short model (two h). Unacceptable divergence PE (-5.8%/ h) of the Kataria model might be caused by the delivery method in its model development, where 38% of patients received propofol by bolus without continuous infusion. Divergence PE of all three PK models developed using bolus dosing only (the Saint-Maurice, Shangguan, and Murat) also had unacceptable PE values <-7.1%/ h (Table 3) . In these three models, typical PE values from 30 to 90 min (Fig. 3) . The general-purpose Schü ttler model developed using a large dataset had acceptable predictive performance. A large sample size from not only Table 4 Comparison of median prediction error (MDPE) and median absolute prediction error (MDAPE) among the present and previous studies. The ranges of measured Cp of propofol were 1.1-4.1 lg ml À1 in the present study, over 0-14 lg ml À1 (most samples lay over 0-9 lg ml À1 ) in the Sepulveda's study, and over 0 23 lg ml À1 (most samples lay over 1-13 lg ml
À1
) in the Coppen's study. NA: not applicable. *The age-adjusted weight-proportional model was applied in the present and Coppens' studies, while the weight-proportional model was applied in the Sepulveda's study
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Present study Sepulveda's study 5 Coppens children but also adults might improve predictive ability in children. This suggests the possibility that a general-purpose model might be useful for children, although our population did not cover infants < three yr old or adolescents.
Divergence PE was applied to evaluate predictive performance in the present study to clarify the time-related PE shift over time. As other PE derivatives, MDPE, MDAPE, and Wobble and performance metrics also assess the predictive performance but not the influence of time, we decided to use divergence PE as the primary outcome. Divergence APE also evaluates the time-related predictive performance, and is feasible to evaluate whether real Cp decreases when predicted Cp maintains constant using TCI. In the two acceptable PK models, divergence PE values were -1.9% h À1 and -2.8% h À1 , (i.e. PE shifted -19% and -28% over 10 h), whereas divergence PE values were unacceptably negative ( -5.8% h
À1
) in five of assessed eleven PK models. When divergence PE is negative, real propofol Cp decreases over time during a constant targeted plasma concentration using TCI, resulting in possible awareness. As MDPE and MDAPE do not describe the influence of time, divergence PE is an important metric for evaluation of PK models applied to long durations.
The MDPE and MDAPE values in the present study are overall smaller than for two previous studies. 5 11 (Table 4) We collected all samples at lower measured Cp up to 4.1 lg ml À1 during steady-state, while Cp was measured during both steady-state and non-steady-state in the previous studies. This suggests that most models overestimate propofol Cp at lower concentrations. Coppens' and colleagues 11 showed that predicted Cp was underestimated at higher Cp and overestimated at lower Cp. The distribution clearances from central to peripheral compartments might be underestimated at higher propofol Cp than for our Cp range between 1-4 lg ml À1 during the short period after the increase of infusion rate. TCI with an inappropriate PK model that underestimates CP during bolus or rapid infusion, could cause an undesired overdose resulting in severe side-effects.
As we studied long-duration anaesthesia, venous blood samples were collected only during steady-state to avoid extensive blood loss in these children. As predictive performance of a PK model could be different when adding non-steady-state information, 29 model performance should be confirmed in other studies 5 11 non-steady-state conditions.
A limitation is that the present study assessed PK model performance in lean children. As all two acceptable PK models include total body weight but not another adjusted body weight such as free fat mass 30 31 as a covariate, the models might underpredict propofol Cp in obese children. Another limitation is that the model performance over long-duration infusion in infants, adolescents, and after the end of long-duration propofol administration are still unknown. Moreover, the present study provides population information and does not clarify which model is the best for an individual patient. Further investigations are necessary to assess these limitations. We found that the Short and Schü ttler models acceptably predicted propofol Cp over long-term infusion up to 545 min in lean children aged three to 11 yr. These models might be preferable for TCI in long-duration propofol anaesthesia in children. As the present study examined predictive performance at steady-state, the model performance at non-steady-state should be confirmed in other clinical situations. The Short model with simple pharmacokinetic parameters only including total body weight as a covariate, had the best predictive performance for the present dataset. As the Schü ttler model has the type of blood sample (arterial or venous) as a covariate, one should predict venous Cp in clinical practice for children when applying the results of the present study. As the venous samples were collected during steady-state, the results of this study should not be applied during non-steady-state such as short period after a bolus or dose rate change. Other PK models (Paedfusor, Shangguan, and Saint-Maurice) had significant negative divergence PE, so one should be aware these three models have a higher possibility of decrement of real Cp when the predicted Cp maintains constant using TCI.
